IL-34 is as a cytokine promoting osteosarcoma progression by increasing the tissue vasculature, by stimulating the recruitment of macrophages and their differentiation toward M2 phenotype. Consequently, IL-34 appears as a pro-metastatic regulator in osteosarcoma.
IL34 produced by cancer cells is also involved in immunosuppression and chemoresistance.
We have developed an antibody binding IL34 with a high affinity. The IL34 antibody are capable of inhibiting IL34-mediated cell proliferation and intracellular signal transduction
By using a anti-IL34 antibody, we observed a total blockade of tumour progression in a syngenic model of osteosarcoma.
Prevention of tumor growth and metastatic
Possible combination with conventional chemotherapy
No side effect
Breast, prostate and lung cancer
Stade de développement
IN VIVO - Preuve de concept
Laboratoire de recherche
UMR_S 1238 - PHY-OS
Équipe de recherche
Sarcomes Osseux et Remodelage des Tissus Calcifiés
Propriété intellectuelle associée
EP : EP14199494 - filed on the 12-19-2014
WO - CA,EP,JP,US